Boehringer Ingelheim founding sponsor of AHA's Cardiovascular-Kidney-Metabolic Health Initiative 

Affecting over one billion lives globally, cardiovascular renal and metabolic diseases are among the leading causes of death worldwide.  Boehringer Ingelheim is committed to reducing the burden and improving outcomes for people living with these diseases and their families.  

"Cardiovascular, kidney and metabolic diseases together represent one of the fastest growing health challenges of our time," says Carinne Brouillon, Head of Human Pharma at Boehringer Ingelheim. "Which is why we at Boehringer are delighted to support the American Heart Association with this critical initiative that will promote education and awareness as well as pinpoint new research– all critical areas of focus for us as a company, where we have rich history and knowledge." 

• The initiative aligns with Boehringer Ingelheim's commitment to improve patient lives and to address gaps in clinical care through best-practice, guideline-focused solutions. 

• The sponsorship fosters collaborations with healthcare professionals, academic institutions, patient organizations, policy makers, and digital health providers to facilitate the co-creation of evidence-based solutions.  

• The CKMH Initiative will address gaps in clinical care and support the development of guidance for early and holistic treatment in practice. The initiative will involve 150 hospitals and sites across the nation, reaching over 265,000 patients. 

Cardiovascular, renal and metabolic diseases are interconnected, can co-exist and amplify one another, but their management is often fragmented. By supporting this initiative, Boehringer Ingelheim furthers its advocacy for an integrated approach to treatment and early prevention by diagnosing and managing these diseases as connected conditions. 

More information about the CKMH Initiative can be found in the AHA press release here: